CA
NZ
UK
AU
IND
US
According to reports dated October 30, 2026, Jin Medical said it had completed the transfer of an 80% stake in Zhongjin Kangma Information Technology (Jiangsu), held by itsSubsidiaryChangzhou Zhongjin Medical, on October 19. Had the transfer missed an October 31 deadline, the company would …
Absci is a biotechnology company that uses artificial intelligence and generative design to discover and develop antibody-based drug candidates. That puts it at the intersection of early-stage drug development, where value depends on future trial outcomes, and AI, where enthusiasm has driven valuations across …
For a biotechnology company, a regulatory decision date is often one of the most important events on the calendar. When it moves, it resets the timing of potential revenue,Marketingplans and cash needs and introduces fresh uncertainty. A review extension can occur for many reasons, …
According to market reports citing regulatory filings, Corporate GP VI Ltd., an entity linked to theInvestmentfirm Qiming and described as a major shareholder, sold stock in three transactions this week: 132,524 shares on October 26 at an average of $30.52, 84,894 shares on October …
A review of available information did not identify anEarningsrelease, guidance change, filing or other announcement that would account for a decline of this size. Suggesting the drop reflected a specific concern about theBusinesswould be speculation. What can be stated is that the stock fell …
Growth of 13% is a solid result for many companies, but share prices are driven less by absolute growth than by how results compare with what investors had priced in. When a company's ownLeadershipsays revenue fell short, the market tends to reassess the quarter …
According to the results release dated October 30, third-quarter revenue was $16,209 million, up 7% at constant exchange rates, and nine-month revenue reached $46,881 million. CoreEarnings Per Sharefor the quarter were $2.79, against $2.60 expected, while reported earnings per share were $2.02. Growth was …
Revenue came in at $32.6 million, up 52% from a year earlier and well ahead of the roughly $28.4 million analysts expected. Chief executive Joseph DeVivo said the result beat the top end of the company's own guidance. Adjusted grossMarginwidened by about nine points,Gross …
An upward revision to guidance tends to carry more weight than a single quarterly beat, because it signals that management expects the stronger performance to continue through the rest of the year. A raise to operating profit guidance is particularly meaningful where reimbursement rates, …
Third-quarter revenue rose 39% to $139.4 million from $100.1 million. Testing services, the core business, brought in $119.2 million, up from $72.2 million, on roughly 75,900 tests, which is where CareDx earns money from blood tests that help doctors monitor transplant patients for signs …
Please wait processing your request...